����������

Arpeggio Bio, a preclinical company whose technology provides a mechanistic understanding of how drugs work, today announced that it has closed a $3.2 million seed financing round, which was oversubscribed by over $2 million. Funding will support

Stress granules comprised of RNA (red) and protein assemblies (green) formed in part through RNA-RNA interactions. A recent study from ���������� researchers shows that cells must actively work to keep sticky molecules, known as ribonucleic acid (